Business
Ainos, Inc. Announces Strategic Partnership with Taiwan Tanabe Seiyaku to Advance Manufacturing and Taiwan Market Promotion of Sjögren's Syndrome Drug
San Diego, California--(Newsfile Corp. - December 2, 2024) - Ainos, Inc. (NASDAQ: AIMD) (NASDAQ: AIMDW) ("Ainos" or the "Company"), an innovative healthcare
About this update from Ainos, Inc.
[{"type":"text","content":"San Diego, California--(Newsfile Corp. - December 2, 2024) - Ainos, Inc. (NASDAQ: AIMD) (NASDAQ: AIMDW) (\"Ainos\" or the \"Company\"), an innovative healthcare company focused on advanced AI-driven point-of-care testing (\"POCT\") and low-dose interferon therapeutics, today proudly announced the signing of a strategically significant Memorandum of Understanding (MOU) with Taiwan Tanabe Seiyaku Co., Ltd., a subsidiary of Mitsubishi Tanabe Pharma Corporation in Japan, brings extensive pharmaceutical development and manufacturing expertise to the partnership. The collaboration aims to advance the manufacturing and Taiwan market promotion of Ainos' groundbreaking Sjögren's syndrome drug, VELDONA®. Both parties may work under the terms of the MOU to further define the partnership.\nMarket Demand for Sjögren's Syndrome Treatment\nSjögren's syndrome is an autoimmune disease affecting millions of patients worldwide, with a significant unmet need for effective treatments. As the global population ages and awareness of the disease increases, the demand for therapeutic solutions is growing rapidly. According to market analysis, the global Sjögren's syndrome market is projected to reach billions of dollars in the next five years. Ainos believes VELDONA® will provide a much-needed, innovative treatment option for millions of patients and fulfill this pressing market demand.\nVELDONA®'s Clinical Progress and Success\nAinos has dedicated years to the development of Sjögren's syndrome treatments, with VELDONA®, a low-dose oral interferon-alpha, showing remarkable potential in clinical trials. Previous studies have demonstrated that VELDONA® can significantly alleviate patient symptoms, improve quality of life, and effectively control disease progression. The drug has shown strong tolerability and safety, establishing a solid foundation for further large-scale global clinical trials.\nPartnership with Taiwan Tanabe Seiyaku\nTaiwan Tanabe Seiyaku, as a subsidiary of Mitsubishi Tanabe Pharma, offers extensive experience in pharmaceutical development and market expansion. As part of this partnership, Taiwan Tanabe Seiyaku may collaborate with Ainos on the manufacturing and promotion of VELDONA® to meet market demand. Both parties will clarify the specific details and responsibilities of the partnership as stipulated in the MOU agreement.\nGlobal M...